Therapeutic Efficacy of Delta-Like Ligand 4 Gene Vaccine Overexpression on Liver Cancer in Mice

Yi Yu, MD1, Yang Zhao, MD2, Guangming Zhou, MD3, and Xiang Wang, MD1

Abstract
Delta-like ligand 4 is a notch ligand that is predominantly expressed in the endothelial tip cells and plays essential roles in the regulation of angiogenesis. In this study, we explored the therapeutic effects of delta-like ligand 4 gene vaccine overexpression on the syngeneic model mouse model of liver cancer and the underlying mechanisms. Mouse hepatocellular carcinoma cell line H22-H8D8 was used to generate subcutaneous syngeneic model liver cancer in Kunming mice, and the effects of recombinant plasmid pVAX1 containing delta-like ligand 4 vaccine on tumor growth was examined. Compared to controls, delta-like ligand 4 vaccination reduced syngeneic model tumor size by 70.31% (from 17.11 ± 9.30 cm³ to 5.08 ± 2.75 cm³, P = .035) and tumor weight by 34.19% (from 6.26 ± 3.01 g to 4.12 ± 2.52 g, P = .102), while the mouse survival was significantly increased (from 27.7 ± 6.0 days to 33.1 ± 6.1 days, P = .047). High level of delta-like ligand 4 antibody, together with a significantly increased number of CD4+ and decreased CD8+ cells were identified in the mouse peripheral blood serum samples after delta-like ligand 4 immunization. In addition, elevated serum levels of interleukin 2, interleukin 4, and interferon γ were detected in the delta-like ligand 4–vaccinated mice when compared to the controls. Further studies have revealed increased CD31 and decreased Ki67 expression in the syngeneic model tumor tissues of vaccinated mice. Taken together, our studies suggest that delta-like ligand 4 gene vaccine can inhibit the growth of hepatocellular carcinoma in mice through inhibiting tumor angiogenesis and boosting antitumor immune responses. Hence, delta-like ligand 4 gene vaccination may be a promising strategy for the treatment of transplanted liver cancer.

Keywords
delta-like ligand 4, DNA vaccine, anti-tumor effect, immunotherapy, hepatocellular carcinoma, immune response

Abbreviations
DLL4, delta-like ligand 4; ELISA, enzyme-linked immunosorbent assay; HCC, hepatocellular carcinoma; IFN, interferon; IgG, immunoglobulin G; IL, interleukin; KM, Kunming; PBS, phosphate-buffered saline; PEA, polyester amine; TUNEL, TdT-mediated dUTP Nick-End Labeling; VEGF, vascular endothelial growth factor.

Introduction
Hepatocellular carcinoma (HCC) is the fifth most common and the second leading cause of cancer-related death worldwide. Hepatocellular carcinoma is particularly common in Asian countries including China. Most of the patients with HCC are diagnosed at advanced stage due to a lack of specific diagnostic marker, and patients with advanced HCC generally have very poor prognosis, as the tumors are generally resistant to the existing treatments and are prone to local and distant metastasis. Curative treatments such as surgery and liver

1 Key Laboratory of Digestive Disease, Gansu Province, Lanzhou University Second Hospital, Lanzhou, China
2 Key Laboratory of Digestive System Tumors, Gansu Province, Lanzhou University Second Hospital, Lanzhou, China
3 Department of Space Radiobiology, Key Laboratory of Heavy Ion Radiation Biology and Medicine, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China

Corresponding Author:
Xiang Wang, Key Laboratory of Digestive Disease, Department of Gastroenterology, Lanzhou University Second Hospital, 82 Cuiyingmen, Lanzhou 730030, China.
Email: wangxiang@lzu.edu.cn
transplantation are only possible for less than 20% of patients with early diagnosed HCC, with the reported 5-year post-surgery recurrence rate of 75%. Clearly, more effective treatments are urgently needed.

Immunotherapy for cancers has been regarded as one of the most important and promising advances in cancer therapy. Ideally, cancer treatments should specifically eradicate tumor cells without damaging normal cells. In this aspect, immunotherapy differs from the traditional cancer therapies such as surgery, radiation, and chemotherapy in that it can be made highly tumor-specific. The goal of immunotherapy is to recover or boost the host immune response to tumor-associated antigens or any specific proteins expressed by tumor cells through regulating the body’s immune system.

Antitumor gene vaccines have become a promising tool for anticancer immunotherapy because they can exert a specific antitumor effect through increasing the tumor antigen expression on the host cells, which then reinforce the innate immune function. Antitumor gene vaccines differ from traditional vaccines in that the former can induce both humoral and cellular immune response, whereas the traditional vaccines only induce antigen-specific humoral immune response. Gene vaccine may open a new avenue for cancer immunotherapy.

Functional angiogenesis is essential for tumor development, growth, invasion, and metastasis. As such, angiogenesis has been demonstrated a promising approach for the treatment of solid tumors, with blocking vascular endothelial growth factor (VEGF) receptor signaling pathway being a classical example. However, despite a short improvement in the overall survival rate in patients receiving the combinatorial therapy of VEGF monoclonal antibody and traditional chemotherapy, most patients developed resistance to anti-VEGF treatments after a period of drug exposure. Clearly, drug resistance is a critical hurdle for successful cancer treatment, and more effective approaches need to be developed.

Delta-like ligand 4 (DLL4), an important ligand for notch signaling, is a critical component of neovascularization both under the physiological and the pathological conditions. Delta-like ligand 4 is localized downstream of the VEGF signaling and plays a tumor-suppressive role in tumor cells.

Recent studies have identified that DLL4 is a potential drug target, as DLL4 blockade (eg, by anti-DLL4 antibodies) inhibited tumor growth despite it increased blood vessel density. It is well known that structural defects and dysfunction of neovascularization impair the ability of tumor tissues to grow. Since DLL4 is predominantly expressed in endothelial tip cells during angiogenic sprouting, it constitutes a unique target for cancer immunotherapy. Thus, targeting DLL4 may be a useful approach for the treatment of anti-VEGF therapy-resistant HCC. So far, treatment of liver cancer with gene vaccine has been rarely reported.

In this study, we aimed to investigate the therapeutic efficacy of DLL4 gene vaccine using syngeneic model liver cancer in mice as a model. We demonstrated that DLL4 gene vaccine inhibited syngeneic model tumor growth via disrupting functional tumor angiogenesis and inducing both humoral and cellular immune response in mice.

Materials and Methods

Reagents and DNA Constructs

The pVAX1-DLL4 gene vaccine plasmids were kindly provided by Dr Qi Qi He (Key Laboratory of Urinary Diseases of Gansu Province; Department of Urological Surgery, Lanzhou University Second Hospital, Lanzhou, China). FITC-conjugated DLL4 antibody (Cat No: 131093) was purchased from Zeyi Biological Co, Ltd. Rabbit polyclonal antibody against human DLL4 (Cat No: ab7280) was purchased from Abcam. FITC-conjugated rat anti-mouse CD4 and PE-labeled rat anti-mouse CD8 were purchased from Biologend. Mouse polyclonal antibodies against CD31 and Ki67 were purchased from Zhongshan Golden Bridge Biological Technology Co Ltd. Antibody against β-actin was purchased from Santa Cruz Biotechnology. All primary antibodies were diluted at 1:200 in phosphate-buffered saline (PBS). Secondary antibodies including horseradish peroxidase–conjugated goat anti-rat immunoglobulin G (IgG) and anti-rabbit IgG were purchased from Zhongshan Golden Bridge Biological Technology Co Ltd. TdT-mediated dUTP Nick-End Labelling (TUNEL) Assay Kit (Cat No: G3250; Promega) was purchased from Gansu Baoxin Biological Technology Co Ltd. ECL Western Blotting Detection Kit was purchased from GEHealthcare Life Science.

Cell culture, transfection, and Western blot

Mouse HCC cell line H22-H8D8 (H22) was purchased from Focusbio and were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 1% glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin. Cells were cultured in fresh culture medium for 12 hours before transfection. To optimize the transfection conditions, PEAs (0.15 µg/µL) were mixed with pVAX1-DLL4 DNA at various volume ratios (1:0.5, 1:1, 1:2, and 1:4) and incubated at room temperature for 15 minutes to generate the DNA-lipid complexes. H22 cells were then transfected by adding these complexes drop wise into the culture medium. After 48 hours, the transfected cells were lysed with modified radioimmune precipitation assay buffer (Cell Signaling Technology), total proteins were extracted, and the concentration was measured by BCA protein assay kit (Beyotime).

For Western blot analysis, 25 µg of total cell proteins from each treatment condition were subjected to sodium salt polyacrylamide gel electrophoresis. The proteins were transferred to polyvinylidene fluoride membrane (Millipore) at 120 v for 1.5 hours and probed with primary antibodies against rabbit-anti human DLL4 (1:500) or β-actin for 1.5 hours at room temperature. After 3 washes in Tris-buffered saline with 0.05% Tween, the membranes were incubated with appropriate
secondary antibodies (peroxidase-conjugated goat anti-rabbit immunoglobulin or goat anti-mouse immunoglobulin, both from Santa Cruz Biotechnology). The signals were detected by Amersham ECL Western Blotting Detection Kit.

Based on our optimization studies, we have determined that 4 g per reaction was the most optimal dose for the pVAX1-DLL4 gene vaccine plasmids that can give most efficient transfection. Hence, in the subsequent studies, 4 g of plasmids were used.

Syngeneic model, tumor model, and DNA vaccination. Male specific pathogen free Kunming (KM) mice (4 weeks, average weight 14.8 ± 2.7 g) were purchased from the Experimental Animal Center of Gansu Provincial College of Traditional Chinese Medicine. Each mouse was inoculated with H22 cells (2 × 10^6) in the left hind leg. Tumors were measured with a caliper weekly, and the tumor volume was calculated using the formula: L × W × π/6, where L is the largest diameter (mm) and W is the smallest diameter (mm). When the tumor mass reached approximately 5 × 5 mm, mice were randomized into 2 groups and were intramuscularly injected into the quadriceps with 50 μg of DLL4 gene vaccine (n = 14) or the same amount of pVAX1 empty plasmids (n = 14). Mice were immunized once every 2 weeks for a total of 3 doses. Twenty-four hours prior to each dose of vaccine, each mouse was injected with 200 μL of 0.25% bupivacaine at the same site of vaccine injection. Four weeks after the last immunization, mice were killed. All animal studies were approved by Lanzhou University Institutional Animal Care and Use Committee.

Detection of DLL4 antibody. One week after the last immunization, serum samples were collected for the detection of DLL4-specific antibody by using DLL4 ELISA kit (JL19084, Shanghai Jianglai Biotechnology, Co, Ltd). Briefly, 96-well enzyme-linked immunosorbent assay (ELISA) plates were prepared by coating with human DLL4 antibody. Absorbance was measured at 450 nm with an ELISA reader, per the instructions from the supplier.

Assessment of Interleukin-2, Interleukin-4, and interferon γ by ELISA. Peripheral blood samples were collected from mice via eye ball and diluted 100 times with PBS. Interleukin-2 (IL-2), Interleukin-4 (IL-4), and interferon γ (IFN-γ) titers were evaluated by respective ELISA kits (ZSGB Bio). Normal mouse serum samples were used as negative controls. Absorbance was read at 450 nm. All samples and controls were measured in duplicates.

Flow cytometry analysis. Anticoagulant blood sample from each mouse (100 μL) was incubated with 2 μL of FITC-labeled rat anti-mouse CD4 (0.5 mg/mL) or 5 μL of PE-labeled rat anti-mouse CD8 (0.2 mg/mL; BioLegend) for 30 minutes, followed by incubating with 2 mL of ammonium–chloride–potassium lysis buffer for 15 minutes in the dark and centrifuged for 5 minutes at 1500 rpm. After 2 washes with 2 mL of PBS, the resultant cell pellet was resuspended in 500 μL of PBS and analyzed by Calibur Flow Cytometry.

Immunohistochemical staining. The expression of CD31 and Ki67 in the syngeneic model tumor tissues was stained with mouse polyclonal antibodies against CD31 and Ki67. Mouse IgG (Abcam) was used as a control. Slides were developed with diaminobenzidine tetrahydrochloride and counterstained with hematoxylin. The staining results were semi-quantitatively scored from 3 randomly chosen fields as previously reported.

TdT-mediated dUTP nick-end labelling assay. The TUNEL assay was used to detect apoptosis in paraffin-embedded syngeneic model tumor tissues. The TUNEL procedure was performed according to the manufacturer’s instruction. Briefly, the sections were treated with 1 mg/mL of DNase I at room temperature for 10 minutes as a positive control. Paraffin-embedded blocks were cut into sections of 5-μm thickness, incubated with 100 μL of protease K for 10 minutes, followed by incubation with 50 μL of rTdT buffer for 60 minutes. The sections were stained with NaCl and sodium citrate solution for 15 minutes and counterstained with pyridine iodide solution for 15 minutes in the dark. The slides were observed under a fluorescence microscopy (ZEISS LSM 510 META) at 520 ± 20 nm excitation and 620 nm emission. Each slide was scored in 10 random fields.

Statistical Analysis

All data were analyzed using SPSS 13.0 software (SPSS). Significant difference was determined by unpaired, 2-tailed Student t test or independent sample t test. A P < .05 was considered statistically significant.

Results

DLL4 Gene Vaccination Inhibits Syngeneic Model Tumor Growth and Prolongs Animal Survival

To investigate whether pVAX1-DLL4 gene vaccine exerts antitumor effects in vivo, we established syngeneic model liver cancer model in KM mice using mouse HCC cell line H22. As described in the “Materials and Methods” section, each mouse was inoculated with 2 × 10^6 H22 cells that were previously transfected with the combination of pVAX1-DLL4 DNA and PEA (0.15 μg/μL) at a volume ratio of 1:1. Polyester amine is a low-molecular-weight polyester, poly-ε-caprolactone, and polyethyleneimine that has been shown to significantly enhance gene transfection. With this transfection condition, we achieved a transfection efficiency of 50% to 70% as confirmed by fluorescence microscopy (Figure 1A and B) and Western blot analysis (Figure 1C).

Following cell injection, syngeneic model tumors were successfully established in 28 mice (82.35%, total mice 34) within 7 to 14 days of tumor cell injection. Two weeks after tumor cell translation, the tumor-bearing mice were randomly divided into 2 groups: DLL4 gene vaccine group and control group (mice receiving pVAX1 empty plasmids). We observed that 37 days after cell inoculation, 64.7% of mice receiving DLL4...
immunization survived, whereas only 16.7% of mice receiving control vaccine survived (Figure 2A). The average survival time for mice receiving DLL4 vaccines was 33.1 ± 6.1 days, which was significantly longer than the mice in control group (27.67 ± 6.02 days, $P = .047$).

Upon completion of the *in vivo* experiments, the syngeneic model tumors were analyzed. As illustrated by the tumor volume analysis, DLL4 vaccines led to a significant (70.3%) reduction in the syngeneic model tumor volumes (5.08 ± 2.75 cm³ in DLL4 group vs 17.11 ± 9.30 cm³ in control group).

**Figure 1.** H22 cells were transiently transfected with FITC-DLL4 plasmid. A, Transfected cells were viewed under a fluorescent microscope. B, Phase-contrast image of the same field. Magnifications: ×200. C, The expression of Delta-Like Ligand 4 (DLL4) in the transfected H22 cells was confirmed by Western blot. a, Control (no transfection); b, Cells transfected with Lipo2500 alone; c, Cells transfected with DLL4 plasmids and polyester amines (PEAs) at a ratio of 1:1.

**Figure 2.** Effects of the delta-like ligand 4 (DLL4) gene vaccine on tumor growth and mouse survival. A, Animal survival analysis. B, Tumor volume. C, Tumor weight. D, Typical pictures of excised xenograft tumors.
control group, $P = .035$; Figure 2B and D). A reduction in tumor weight by 34.2% was also observed following DLL4 vaccination (4.12 ± 2.52 g in DLL4 group vs 6.26 ± 3.01 g in control group, $P = .102$), although the difference was not statistically significant (Figure 2C and D). Representative pictures of syngeneic model tumors are shown in Figure 2D. These results demonstrated the therapeutic efficacy of DLL4 gene vaccine in the mouse model of HCC.

The DLL4 Gene Vaccine Elicits Both Humoral and Cellular Immune Responses in Mice

To explore the potential mechanisms of the anticancer effects of DLL4 gene vaccine, we evaluated the both humoral and cellular immune responses. High titer of DLL4-specific antibody was detected in the serum samples of the DLL4-vaccinated mice (optical density [OD] value: 1.32 ± 0.21) but not in the mice immunized with empty vector (OD value: 0.47 ± 0.11; $P = .045$; Figure 3A). These results indicate that the DLL4 gene vaccine stimulated antigen-specific humoral immune response in mice.

We then measured the number of CD4$^+$ and CD8$^+$ cells in the peripheral blood by flow cytometry. As shown in Figure 3B and C, a significantly higher level of CD4$^+$ cells were detected in DLL4-vaccinated mice as opposed to the control mice (32.41 ± 4.19% vs 15.67 ± 7.02%, $P = .001$). Meanwhile, a significantly lower level of CD8$^+$ cells was seen in the DLL4-vaccinated mice as compared to the control mice (12.62 ± 7.03%, 20.20 ± 6.45%, $P = .043$).

We further measured the serum levels of cytokines that are known to be secreted by activated T lymphocytes and are commonly used as surrogate markers of cytotoxic lymphocyte (CTL) activity. As shown in Figure 3D, significantly increased concentration of IL-2, IL-4, and IFN-γ was seen in the DLL4-vaccinated mice as compared with the control mice. These results indicate that DLL4 gene vaccine enhanced and provoked immune responses.

DLL4 Gene Vaccine Induces Defective Tumor Angiogenesis and Decreases Cell Proliferation in Syngeneic Model Tumor

Since the DLL4 is predominantly expressed in the endothelial cells and is involved in the regulation of angiogenesis, we examined the impact of DLL4 vaccination on tumor vascularity by detecting the expression of CD31, a marker for neovascularization in the syngeneic model tumor tissues. As shown in Figure 4A, DLL4 vaccination led to an increased CD31 expression in the syngeneic model tumor tissues. In addition, DLL4 vaccination also caused a marked reduction of cell proliferation as indicated by reduced expression of Ki67 (Figure 4A). However, DLL4 vaccination did not cause significant apoptosis in the syngeneic model tumor tissues as revealed by TUNEL assay (Figure 4B).

Delta-Like Ligand 4 DNA Vaccination Does Not Induce Significant Adverse Effects and Toxicity in Mice

To address whether DLL4 gene vaccine exerts any adverse effects to mice, we conducted a careful evaluation on the impact of DLL4 gene vaccine on the general health and blood biochemistry of the vaccinated mice.

Mice immunized with DLL4 gene vaccine did not have any obvious abnormalities in food intake, drinking, fur color, urine production, bowel movement, and overall activity.

Upon examining the blood biochemistry (Table 1), DLL4 immunized mice showed a significant increase in white blood cells when compared to the control mice ($F = 0.821, t = 3.482, P = .006$). DLL4 vaccine did not show any hepatic and hematological toxicity.

Discussion

Gene vaccines, also known as nucleic acid vaccines, are a new class of therapeutic vaccination for cancers. Unlike the traditional attenuated vaccines and protein subunits which mainly induce humoral immune response, gene vaccines can stimulate
both cellular and humoral immune responses. As previously reported, gene vaccines could elicit both prophylactic and therapeutic effects in prostatic adenocarcinoma.12,35-37 Our current study clearly demonstrated that DLL4 vaccines could inhibit the growth of syngeneic model liver cancer in mice.

In gene vaccination, vaccine delivery is a critical issue that may affect the efficacy of vaccination. Hence, effective delivery approaches must be used to ensure the efficient and safe delivery of vaccinating genes to the recipients. Muscle injection is the most cost effective and a safe approach when compared to other approaches such as scratches, microinjection, ultrasound, and electroporation.38-43 Direct intramuscular injection of naked plasmid DNA with bupivacaine has been shown to induce a strong and long-term immune response to the antigen encoded by the vaccinating gene.31 It was reported that pVAX1-DLL4 gene vaccination via muscle injection could mobilize the antigen-presenting cells (APCs) in the host bone marrow,44-46 which can then activate the cytotoxic lymphocytes (CTL) via major histocompatibility complex (MHC) I pathway. However, it should be noted that the maturation and infiltration of APCs can be affected by tumors.47,48 Based on our optimization studies in vitro, the combination of recombinant pVAX1-DLL4 plasmids and PEAs at a ratio of 1:1 gave the most efficient transfection efficiency. Hence, this condition was used in the subsequent studies and was shown to achieve a successful up-regulation of DLL4 in recipient mice.

In our study, outbred KM mice rather than the classical nude mice or inbred mice were used because the outbred KM mice show little variation in gene purity while minimum genetic heterogeneity is maintained.49,50 In addition, KM mice can produce several biologically active peptides that are capable of stimulating the lymphoid progenitor cells into mature T lymphocytes. Hence, this type of mice is a preferred model for studying the effect DLL4 vaccine on immune response. Tumor development may cause immune dysfunction.51 CD4+ T cells boost the antitumor immune response, whereas CD8+ T lymphocytes have the opposite effects on the antitumor immunity.52 With the right animal model, we have observed that DLL4 vaccine provoked immune responses in mice. Due to the lack of sufficient tissues, we were unable to examine the extent of the infiltration of CD4+ and CD8+ T lymphocytes. However, we observed that vaccination with DLL4 gene vaccine increased CD4 but decreased CD8 counts in the peripheral blood, indicating DLL4 gene vaccine possesses antitumor effects.

Indeed, we have observed a significant reduction of Ki67 expression in the syngeneic model tumors. DLL4-induced immune response is also supported by the significant induction of several key pro-inflammatory cytokines, including IL-2, IL-4, and IFN-γ. Numerous studies have shown that these cytokines are also associated with antitumor effects. For example, IL-2 produced by CD4+ T cells, CD8+ T cells, and large

Table 1. Blood Biochemistry in DLL4-Immunized Mice.

| Group | ALT, U/L | AST, U/L | WBC, 10^9/L | RBC, 10^12/L | HB, g/L | PLT, 10^12/L |
|-------|----------|----------|-------------|--------------|---------|--------------|
| Control | 48.2 ± 11.89 | 44.25 ± 15.52 | 6.37 ± 3.88 | 8.23 ± 5.11 | 105 ± 27.92 | 191.25 ± 120.19 |
| Vaccine | 50.0 ± 17.58 | 49.42 ± 23.51 | 18.15 ± 6.09 | 6.24 ± 3.42 | 98.5 ± 18.90 | 191.87 ± 163.21 |

Abbreviations: HB, hemoglobin; PLT, platelets; RBC, red blood cells; WBC, white blood cells.

P = .006.
granular lymphocytes can stimulate nature killer cells to secrete various cytokines that are important in antitumor immune response. Interferon γ is an important pro-inflammatory cytokine that induces chemokine secretion, resulting in chemotraction of other immune cells such as macrophages. Hence, increased IFN-γ production may exert antitumor effects through stimulating phagocytosis by macrophages and upregulating MHC class I molecules.

Angiogenesis is an important mechanism for solid tumors to grow and metastasize. As such, antiangiogenic agents have become a class of promising anticancer drugs. However, in our studies, we have observed a significant increase, rather than a decrease of the vascular density, as indicated by increased expression of CD31 in the syngeneic model tumor tissues. Based on the published data and our observation of the syngeneic model tumor tissues, we propose that DLL4 vaccine may have caused “nonfunctional vascular density.” Due to the lack of sufficient tumor tissues, we were unable to examine the messenger RNA or protein level of DLL4 in the tumor tissues directly. Now available data of high-expression anti-DLL4 in blood were consistent with the published literature that engineered DLL4 gene vaccine could induce antitumor effects in mice with a production of specific DLL4 antibodies. It was proposed that when the balance between VEGF and DLL4 in angiogenesis was broken, higher level of VEGF may promote vascular density but do not effectively transport blood because of the reduced vascular integrity caused by DLL4. In our study, we observed high proliferative fraction of vascular cells as demonstrated by increased CD31 positivity but a reduced vascular perfusion caused by DLL4 antibodies.

Induction of apoptosis is an important mechanism by which anticancer agents exert their effects. In our studies, DLL4 vaccine did not cause any apoptosis in the syngeneic model tumors, suggesting that the antitumor effect of DLL4 vaccine was not through induction of tumor cell apoptosis. More studies are required to further clarify the molecular mechanisms of tumor inhibitory effects of DLL4 vaccine.

Further studies showed that the intensity and duration of the induced immune response from DLL4 gene vaccine may be related to a variety of factors, including characteristics of different tumors, surface charge density, and reactive oxygen signals. The observed antitumor effects by the DLL4 vaccine may also be attributed at least partially to the PEAs used as a part of vaccine delivery approach, as this reagent has been reported to stimulate immune responses, enhance local lymphatic drainage, trigger Toll-Like Receptor 9 recognition, activate DC maturation, induce Th1 response, and increase cytokine release in the recipients. All these effects are known to be associated with antitumor effects. More studies are required to further clarify the molecular mechanisms of tumor inhibitory effects of DLL4 vaccine.

An important finding of our study is that DLL4 vaccines did not show any obvious adverse effects, suggesting an acceptable safety profile. In contrast, previously published studies have reported significant toxic effects of DLL4 antibody-mediated inhibition of DLL4 signaling to multiple organs in experimental animals and in a dose-dependent manner increase the ulcerating subcutaneous tumors. Hence, we believe DLL4 vaccine is superior to DLL4 antibody when used for therapeutic purposes.

In conclusion, our data provide solid evidence that DLL4 vaccine holds promise as a novel class of therapeutic strategy for liver cancer.

Authors’ Note
Yi Yu and Xiang Wang contributed equally to this work. This study was approved by Second Hospital of Lanzhou university Ethical Committee (approval no. 2019-176).

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethics Approval and Consent to Participate
This study was approved by Second Hospital of Lanzhou university Ethical Committee (approval no. 2019-176).

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by funding from the National Science Foundation of China (grant no., 30571860).

ORCID iD
Yi Yu https://orcid.org/0000-0002-4891-451X

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. Li J, Zhang YD, Liu S, Li NF, Li H. Study on application of selective hemihepatic vascular control in hemihepatectomy for hepatoma. Chin J Mor Med. 2006;16(15):2331-2333.
3. Venook AP. Treatment of hepatocellular carcinoma- too many options. J Clin Oncol. 1994;12(6):1323-1334.
4. Stacy S, Hyder O, Cosgrove D, et al. Patterns of consultation and treatment of patients with hepatocellular carcinoma presenting to a large academic medical center in the US. J Gastrointest Surg. 2013;17(9):1600-1608.
5. Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroen. 2013;29(3):285-292.
6. Abou-Alfa G, Colombo M. Shaping the future management of hepatocellular carcinoma. Seminars Liver Dis. 2013;33(1): S20-S23.
7. Cheng WF, Hung CF, Chai CY, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 2001;108(5): 669-678.
8. Thakur A, Vaishampayan U, Lum LG. Immunotherapy and immune evasion in prostate cancer. Cancers (Basel). 2013;5(2): 569-590.
9. Liu M, Guo F. Recent updates on cancer immunotherapy. Precis Clin Med. 2018;1(2):65-74.
10. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008;8(2):108-120.
11. Moss RB. Prospects for control of emerging infectious diseases with plasmid DNA vaccines. J Immune Based Ther Vaccines. 2009;7(3):1-9.
12. Rinaldi M, Ria F, Parrella P, et al. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients tumor cells. Cancer Res. 2001;61(4):1555-1562.
13. McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunologic efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol. 2009;27(25):4047-4054.
14. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003;161(6):1163-1177.
15. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3(1):24-40.
16. Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood. 2006;107(3):931-939.
17. Andrawes MB, Xu X, Liu H, et al. Intrinsic selectivity of notch 1 for delta-like 4 over delta-like 1. J Biol Chem. 2013;288:25477-25489.
18. Haller BK, Bráve A, Wallgard E, et al. Therapeutic efficacy of a DNA vaccine targeting the endothelial tip cell antigen delta-like 4 in mammary carcinoma. Oncogene. 2010;29(30):4276-4286.
19. Duarte A, Hirashima M, Benedito R, et al. Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev. 2004;18(20):2474-2478.
20. Hoey T, Yen W-C, Axelrod F, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell. 2009;5(2):168-177.
21. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumor growth by promoting non-productive angiogenesis. Nature. 2006;444(7122):1032-1037.
22. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumor growth by deregulating angiogenesis. Nature. 2006;444(7122):1083-1087.
23. Schemet JS, Jiang W, Kumar SR, et al. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood. 2007;109(11):4753-4760.
24. Hellström M, Phng L-K, Hofmann JJ, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007;445(7129):776-780.
25. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992;3(2):65-71.
26. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465-1468.
27. Orson FM, Kinsey BM, Hua PJ, Bhogal BS, Densmore CL, Barry MA. Genetic immunization with lung-targeting macroaggregated polyethyleneimine-albumin conjugates elicits combined systemic and mucosal immune responses. Immunol. 2000;164(12):6313-6321.
28. He Q. A Pilot Study on Delta-Like Gland 4 as DNA Vaccine in Mice Renal Cell Carcinoma [D]. Lanzhou University; 2012.
29. Liu T, Yu X, Kan B, et al. Enhanced gene delivery using biodegradable poly(ester amine)s (PEAs) based on low-molecular-weight polyethyleneimine and poly(-caprolactone)-pluronic-poly(-caprolactone). J Biomed Nanotechnol 2010; 6(4):351-359.
30. He Z-J, Chen X-X, Cai Q-H, et al. Comparative study of the different calculating and measuring methods in the implanted tumor volume. Chin J Comp Med. 2009;19(9):47-50.
31. Ajiki T, Murakami T, Kobayashi Y, et al. Long-lasting gene expression by particle-mediated intramuscular transfection modified with bupivacaine: combinatorial gene therapy with IL-12 and IL-18 cDNA against rat sarcoma at a distant site. Cancer Gene Ther. 2003;10(4):318-329.
32. Yu YI, Wang W, Song L, et al. Ecto-5‘-nucleotidase expression is associated with the progression of renal cell carcinoma. Oncol Lett. 2015;9(6):2485-2494.
33. McCarthy HO, Wang Y, Mangipudi SS, et al. Advances with the use of bio-inspired vectors towards creation of artificial viruses. ExpertOpin Drug Deliv. 2010;7(4):497-512.
34. Vyas SP, Goyal AK, Khatri K. Mannosylated liposomes for targeted vaccines delivery. Methods Mol Biol. 2010;605:177-188.
35. Pavlenko M, Roos A-K, Lundqvist A, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer. 2004;91(4):688-694.
36. Corr M, Lee DI, Carson DA, Tighe H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med. 1996;184(4):1555-1560.
37. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 1997;89(1):21-39.
38. Liu F, Liang KW, Huang L. Systemic administration of naked DNA: gene transfer to skeletal muscle. Mol Interact. 2001;1(3):168-172.
39. Oosterhuis K, vandenBerg JH, Schumacher TN, Haanen JB. DNA vaccines and intradermal vaccination by DNA tattooing.Curr Top Microbiol Immunol. 2012;351:221-250.
40. Jinturkar KA, Rathi MN, Misra A. Gene delivery using physical methods. In: Misra A, ed. Challenges in Delivery of Therapeutic Genomics and Proteomics. Elsevier; 2010:83-126.
41. Suzuki R, Oda Y, Utoguchi N, Maruyama K. Progress in the development of ultrasound-mediated gene delivery systems utilizing nano- and microbubbles. J Control Release. 2011;149(1):36-41.
42. Hui SW. Overview of drug delivery and alternative methods to electroporation. Methods Mol Biol. 2008;423:91-107.
43. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines. 2012;11(2):189-209.
44. Cyster JG. Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J Exp Med. 1999;189(3):447-450.
45. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994;264(5161):961-965.
46. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096-1103.
47. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res. 1997;3(3):483-490.
48. Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol. 1997;159(2):770-776.
49. Du RJ, Ma YB, Tang H, et al. Expression of hepatitis E virus ORF3 gene fragment in baculovirus system and its immunological character. Chin Med J. 2001;123(4):378-381.
50. Yin Y, Fu W, Fu M. The immune effects of edible fungus polysaccharides compounds in mice. Asia Pac J Clin Nutr. 2007;16(1):258-260.
51. Liao J, Xiao J, Zhou Y, Liu Z, Wang C. Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma. Mol Med Rep. 2015;12(4):6065-6071.
52. Cao Y, Jiang F, Zhang C, et al. Clinical effect of transcatheter hepatic arterial chemoembolization combined with CT guided precision microwave ablation on patients with primary liver cancer. J Pract Hepatol. 2017;20(4):468-471.
53. Smith KA. Lowest dose interleukin-2 immunotherapy. Blood. 1993;81(6):1414-1423.
54. Hancock BW, Harris S, Wheatley K. Adjuvant interferon-alpha in malignant melanoma: current status. Cancer Treat Rev. 2000;26(2):81-89.
55. Suchting S, Freitas C, Le-Noble F, et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci USA. 2007;104(9):3225-3230.
56. Gale NW, Dominguez MG, Noguera I, et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci USA. 2004;101(45):15949-15954.
57. Gridley T. Notch signaling in the vasculature. Curr Top Dev Bio. 2010;92:277-300.